Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the submission of a New Drug Submission (NDS) to Health Canada seeking marketing approval ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE